Amivantamab compared with real-world therapies in patients with NSCLC with EGFR Exon 20 insertion mutations who have progressed after platinum doublet chemotherapy.

被引：5
|
作者：
Minchom, Anna Rachel
Girard, Nicolas
Bazhenova, Lyudmila
Ou, Sai-Hong Ignatius
Gadgeel, Shirish M.
Trigo, Jose
Viteri, Santiago
Backenroth, Daniel
Bhattacharya, Archan
Li, Tracy
Mahadevia, Parthiv
Bauml, Joshua
机构：
[1] Royal Marsden Inst Canc Res, Drug Dev Unit, Sutton, Surrey, England
[2] Inst Curie, Paris, France
[3] Univ Calif San Diego, San Diego, CA 92103 USA
[4] Univ Calif Irvine, Orange, CA 92668 USA
[5] Henry Ford Hlth Syst, Henry Ford Canc Inst, Detroit, MI USA
[6] IBIMA, Hosp Univ Virgen Victoria & Reg, Malaga, Spain
[7] Grp QuironSalud, Ctr Med Teknon, Inst Oncol Dr Rosell, Barcelona, Spain
[8] Janssen R&D, Raritan, NJ USA
[9] Janssen R&D, High Wycombe, PA, England
[10] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.9052
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9052
引用
收藏
页数：2
相关论文
共 50 条
  • [21] EGFR exon 20 insertion mutations in patients with locally advanced or metastatic NSCLC in the German prospective, CRISP Registry real-world cohort (AIO-TRK-0315)
    Griesinger, F.
    Sebastian, M.
    Bethge, A.
    Christopoulos, P.
    Hoffknecht, P.
    Waller, C.
    Benkelmann, R.
    Jaenicke, M.
    Fleitz, A.
    Hanselmann, J.
    Hipper, A.
    Groth, A.
    Weichert, W.
    Nusch, A.
    Rauh, J.
    Fietz, T.
    Illmer, T.
    Depenbusch, R.
    Eberhardt, W. E. E.
    Thomas, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S54 - S55
  • [22] Real-World Treatment Outcomes of Amivantamab in Pre-Approval Access (PAA) Participants with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations (ex20ins)
    Sabari, J.
    Kim, T. M.
    Spira, A.
    Lee, S. H.
    Chang, G. C.
    Shih, J. -Y.
    Hochmair, M. J.
    Schioppa, C. A.
    Schioppa, C. A.
    Panaccione, A.
    Rose, J. B.
    Chioda, M.
    Mahadevia, P.
    Cho, B. C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E23 - E23
  • [23] Real-world treatment outcomes of amivantamab in pre-approval access (PAA) participants with advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (ex20ins)
    Kim, T. M.
    Lee, S-H.
    Chang, G-C.
    Shih, J-Y.
    Hochmair, M. J.
    Sabari, J. K.
    Spira, A. I.
    Schioppa, C. A.
    Rose, J. B.
    Chioda, M.
    Panaccione, A.
    Mahadevia, P.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2022, 33 : S48 - S48
  • [24] Real-World Treatment Patterns and Survival in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations
    Dersarkissian, M.
    Bhak, R.
    Lin, H.
    Li, S.
    Cheng, M.
    Lax, A.
    Huang, H.
    Duh, M.
    Ou, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S681 - S681
  • [25] Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib
    Mok, T. S. K.
    Liu, G.
    Nyaw, S. F.
    Curcio, H.
    Cortot, A.
    Kam, T. Y.
    Descourt, R.
    Chik, Y. K.
    Cheema, P. K.
    Gwinnutt, J. M.
    Churchill, E. N.
    Nyborn, J.
    Curran, E.
    Yin, Y.
    Chong, K.
    Tanaka-Chambers, Y.
    Kretz, J.
    Cadranel, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1698 - S1699
  • [26] Natural History and Real-World Treatment Outcomes for NSCLC Patients with EGFR Exon 20 Insertion Mutation: An IASLC- ASCO CancerLinQ Study
    Behera, M.
    Jiang, R.
    Huang, Z.
    Bunn, B.
    Wynes, M.
    Switchenko, J.
    Scagliotti, G.
    Belani, C.
    Ramalingam, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1116 - S1116
  • [27] Indirect comparison of mobocertinib and real-world therapies for pre-treated non-small cell lung cancer with EGFR exon 20 insertion mutations
    Christopoulos, Petros
    Prawitz, Thibaud
    Hong, Jin-Liern
    Lin, Huamao M.
    Hernandez, Luis
    Jin, Shu
    Tan, Min
    Proskorovsky, Irina
    Lin, Jianchang
    Zhang, Pingkuan
    Patel, Jyoti D.
    Ou, Sai-Hong I.
    Thomas, Michael
    Stenzinger, Albrecht
    LUNG CANCER, 2023, 179
  • [28] A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations
    Sa, Huanlan
    Shi, Yan
    Ding, Chunxia
    Ma, Kewei
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (10) : 7729 - 7742
  • [29] A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations
    Huanlan Sa
    Yan Shi
    Chunxia Ding
    Kewei Ma
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 7729 - 7742
  • [30] Real-World Data of Osimertinib in Patients with Metastatic EGFRm plus NSCLC who Progressed on First-Line EGFR TKIs
    Ma, J.
    Tan, S. H.
    Yin, D.
    Tran, A.
    Tan, D.
    Ang, M.
    Takano, A.
    Lim, K. H. T.
    Kanesvaran, R.
    Jain, A.
    Rajasekaran, T.
    Tan, E.
    Lim, D. W.
    Ng, Q. S.
    Tan, W.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S627 - S628
12345